2021-2022 Faculty/Staff Influenza Vaccine Administration Record

Please answer the following questions

1. Have you ever had a flu vaccine?  ○ YES  ○ NO
2. If yes, did you have a reaction?  ○ YES  ○ NO
3. WOMEN - Are you pregnant or breastfeeding?  ○ YES  ○ NO
4. Are you allergic to eggs? Allergic to Gentamycin?  ○ YES  ○ NO
5. Do you have a fever, illness or active infection?  ○ YES  ○ NO
6. Have you ever had Guillain-Barre' syndrome?  ○ YES  ○ NO
7. Do you have any questions about the vaccine?  ○ YES  ○ NO

I have received and read the information contained in the Vaccine Information handout. I have received and/or had a chance to review the Notice of Privacy Practice. I have had a chance to ask questions and I understand the benefits and risks of the vaccine.

Patient Signature/Guardian/POA ________________________________ Today’s Date:

FOR OFFICE USE ONLY:

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Manufacturer</th>
<th>Lot #</th>
<th>Exp. Date</th>
<th>Amt Given</th>
<th>Injection Site (Deltoid)</th>
<th>Given By:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza Quadrivalent FLUARIX</td>
<td>GSK</td>
<td>9XX32</td>
<td>6/30/2022</td>
<td>0.5 ML</td>
<td>R L</td>
<td>___________________</td>
</tr>
</tbody>
</table>

*CONTAINS NO PRESERVATIVES*

FLUARIX QUADRIVALENT has been standardized according to U.S. Public Health Service (USPHS) requirements for the 2021-2022 influenza season and is formulated to contain 60 micrograms (mcg) hemagglutinin (HA) per 0.5-mL dose, in the recommended ratio of 15 mcg HA of each of the following 4 influenza virus strains (2 A strains and 2 B strains): A/Victoria/2570/2019 (H1N1) IVR-215, A/Tasmania/503/2020 (H3N2) IVR-221 (an A/Cambodia/e0826360/2020 (H3N2)-like virus), B/Washington/02/2019 (B-Victoria lineage), and B/Phuket/3073/2013 (B-Yamagata lineage).